MyMD Pharmaceuticals (NASDAQ:MYMD) Trading Up 3.2%

MyMD Pharmaceuticals, Inc. (NASDAQ:MYMD)’s share price was up 3.2% on Monday . The stock traded as high as $2.69 and last traded at $2.58. Approximately 64,695 shares changed hands during mid-day trading, a decline of 67% from the average daily volume of 194,298 shares. The stock had previously closed at $2.50.

MyMD Pharmaceuticals Stock Up 3.2 %

The company has a market cap of $5.57 million, a price-to-earnings ratio of -0.48 and a beta of 2.29. The company has a fifty day simple moving average of $2.88 and a two-hundred day simple moving average of $6.45.

Institutional Trading of MyMD Pharmaceuticals

An institutional investor recently raised its position in MyMD Pharmaceuticals stock. Cambria Investment Management L.P. lifted its stake in shares of MyMD Pharmaceuticals, Inc. (NASDAQ:MYMD) by 184.8% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 171,570 shares of the company’s stock after buying an additional 111,335 shares during the quarter. Cambria Investment Management L.P. owned 0.38% of MyMD Pharmaceuticals worth $102,000 as of its most recent filing with the SEC. 9.64% of the stock is currently owned by institutional investors.

MyMD Pharmaceuticals Company Profile

MyMD Pharmaceuticals, Inc, a clinical development stage pharmaceutical company, focuses on developing various therapeutic platforms to treat the aging and age-related and autoimmune diseases, and chronic pain, anxiety, and sleep disorders. The company is developing MYMD-1, a drug platform based on a clinical stage small molecule that regulates the immune system and its pro-inflammatory cytokines to prevent and treat autoimmune diseases and age-related illnesses, and a Phase 2 clinical trial for sarcopenia, multiple sclerosis, diabetes, inflammatory bowel diseases, and rheumatoid arthritis; inflammation related depression and anxiety; and COVID-19-associated depression.